Evidence map›Paper›PMID 40453056›Full record

Trial reportBlood neoplasia2024

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.

Ulrich Dührsen, Andreas Bockisch, Bernd Hertenstein, Imke E Karsten, Frank Kroschinsky, Michael Heuser, Andreas Hochhaus, Heinz-Gert Höffkes, Dirk Behringer, Gabriele Prange-Krex and 16 more

Erratum issuedAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Could treatment modification based on early response assessment improve results in DLBCL?Hematology. American Society of Hematology. Education Program · 2025
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Ulrich DührsenKlinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum, Essen, Germany.
Andreas BockischKlinik für Nuklearmedizin, Universitätsklinikum, Essen, Germany.
Bernd HertensteinMedizinische Klinik I, Klinikum Bremen Mitte, Bremen, Germany.
Imke E KarstenMedizinische Klinik A, Universitätsklinikum, Münster, Germany.
Frank KroschinskyMedizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Michael HeuserKlinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule, Hannover, Germany.
Andreas HochhausKlinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.
Heinz-Gert HöffkesTumorklinik, Klinikum, Fulda, Germany.
Dirk BehringerKlinik für Hämatologie, Onkologie und Palliativmedizin, Augusta-Kranken-Anstalt, Bochum, Germany.
Gabriele Prange-KrexOnkologische Gemeinschaftspraxis, Dresden, Germany.
Mareike TomettenKlinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Uniklinik RWTH Aachen, Aachen, Germany.
Martin GrieshammerUniversitätsklinik für Hämatologie, Onkologie, Gerinnungsstörungen und Palliativmedizin, Johannes Wesling Klinikum, Minden, Germany.
Götz U GrigoleitKlinik für Hämatologie, Onkologie und Immunologie, Helios Klinikum, Duisburg, Germany.
Oliver SchmalzKlinik für Hämatologie, Onkologie, klinische Infektiologie und Palliativmedizin, Helios Universitätsklinikum, Wuppertal, Germany.
Karin JordanKlinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Ernst von Bergmann, Potsdam, Germany.
Helga BernhardMedizinische Klinik V, Klinikum, Darmstadt, Germany.
Tobias GaskaKlinik für Hämatologie und Onkologie, Brüderkrankenhaus St Josef, Paderborn, Germany.
Aristoteles GiagounidisKlinik für Onkologie, Hämatologie und Palliativmedizin, Marienhospital, Düsseldorf, Germany.
Roland SchroersMedizinische Klinik, Sektion Hämatologie, Onkologie, Stammzell- und Immuntherapie, Universitätsklinikum Knappschaftskrankenhaus, Bochum, Germany.
Uwe M MartensKlinik für Innere Medizin III, SLK-Kliniken, Heilbronn, Germany.
Gerhard HeldKlinik für Innere Medizin 1, Westpfalz-Klinikum, Kaiserslautern, Germany.
Wolfram KlapperInstitut für Pathologie, Sektion für Hämatopathologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Karl-Heinz JöckelInstitut für Medizinische Informatik, Biometrie und Epidemiologie, Universität Duisburg-Essen, Essen, Germany.
Michael NonnemacherInstitut für Medizinische Informatik, Biometrie und Epidemiologie, Universität Duisburg-Essen, Essen, Germany.
Andreas HüttmannKlinik für Hämatologie und Stammzelltransplantation, Universitätsklinikum, Essen, Germany.
PETAL Trial Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20

Identifiers

PMID40453056
PMCPMC12082160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.